Application of Nanotechnology in Immunity against Infection
Source abstract
Abstract
The immune system has a physiological defense function, protecting the body from infectious diseases. Antibiotics have long been one of the most important means to treat infectious diseases, but in recent years, with the emergence of more and more multidrug-resistant (MDR) bacteria, it has become urgent to find new ways or drugs to treat infectious diseases. Nanoparticles (NPs) have attracted extensive attention owing to the special properties within the particle size range of 1–100 nanometers. In addition, NPs also have special shape symmetry and relative structural stability. The emergence of nanotechnology has brought new light to the widespread existence of MDR by its different antibacterial mechanisms. In addition to antibiotic nanocarriers being able to improve the antibacterial effect of antibiotics, some NPs also have certain antibacterial effect. What is more interesting is that linking functional groups on the surface of NPS as coatings can improve the stability of the whole system and improve the biocompatibility. The present review overviews the development of antimicrobial agents, so as to better understand the causes and mechanisms of antibiotic resistance in most microbial species, and to better think and explore new strategies to solve the problem. At the same time, this review introduces how nanotechnology can be applied to anti-infection immunity and its practical application and advantages in the treatment of infection.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Nanoparticles: synthesis and applications · Antimicrobial agents and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Environment and Sustainable Development in Agriculture, Chinese Academy of Agricultural Sciences, Beijing 100000, China
College of Agriculture, Purdue University, West Lafayette, IN 47907, USA
References (77)
Show source-provided references
1. Nanotechnology and medicine10.1517/14712598.3.4.655 ↗
2. Feynman, R.P. (1960). There’s Plenty of Room at the Bottom: An Invitation to Enter a New Field of Physics, California Institute of Technology.
3. Drexler, K.E. (1986). Engines of Creation: The Coming Era of Nanotechnology, Anchor Books.
4. Cellular nanotechnology: Making biological interfaces smarter10.1039/c3cs60198f ↗
5. Nanocarriers’ entry into the cell: Relevance to drug delivery10.1007/s00018-009-0053-z ↗
6. An overview of nanoparticles commonly used in fluorescent bioimaging10.1039/C4CS00392F ↗
7. Application of anisotropic silver nanoparticles: Multifunctionalization of wool fabric10.1016/j.jcis.2011.01.054 ↗
8. Silver nanoparticles deposited layered double hydroxide nanoporous coatings with excellent antimicrobial activities10.1002/adfm.201102333 ↗
9. Nanoparticle surface and nanocore properties determine the effect on radiosensitivity of cancer cells upon ionizing radiation treatment10.1166/jnn.2013.6087 ↗
10. The role of nanotechnology in combating multi-drug resistant bacteria10.1166/jnn.2014.9527 ↗
11. Why is big Pharma getting out of antibacterial drug discovery?10.1016/j.mib.2003.08.003 ↗
12. Current applications of nanoparticles in infectious diseases10.1016/j.jconrel.2016.01.008 ↗
13. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America10.1086/595011 ↗
14. World Health Organization (2014). Antimicrobial Resistance: Global Report on Surveillance, WHO.
15. Molecular mechanisms of antibacterial multidrug resistance10.1016/j.cell.2007.03.004 ↗
16. Emerging intracellular bacterial infections10.1016/j.cll.2004.05.005 ↗
17. Delivery systems to increase the selectivity of antibiotics in phagocytic cells10.1016/j.jconrel.2007.10.027 ↗
18. “Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era10.1016/j.jconrel.2011.07.002 ↗
19. New ways to treat bacterial infections10.1016/S1359-6446(02)02498-4 ↗
20. Potential impact of nanotechnology on the control of infectious disease10.1016/j.trstmh.2007.07.003 ↗
21. Silver NPs as a new generation of antimicrobials10.1016/j.biotechadv.2008.09.002 ↗
22. Toxicity of gold NPs functionalized with cationic and anionic side chains10.1021/bc049951i ↗
23. Antibacterial properties of nanoparticles10.1016/j.tibtech.2012.06.004 ↗
24. Antibacterial activity of ZnO nanoparticle suspensions on a broad spectrum of microorganisms10.1111/j.1574-6968.2007.01012.x ↗
25. Enhanced efficacy of superparamagnetic iron oxide NPs against antibiotic-resistant biofilms in the presence of metabolites10.1002/adma.201302627 ↗
26. Nanosilver as a new generation of nanoproduct in biomedical applications10.1016/j.tibtech.2010.07.006 ↗
27. Selective toxicity of ZnO NPs toward Gram-positive bacteria and cancer cells by apoptosis through lipid peroxidation10.1016/j.nano.2010.10.001 ↗
28. Does the antibacterial activity of silver NPs depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli10.1128/AEM.02218-06 ↗
29. Agents that increase the permeability of the outer membrane10.1128/mr.56.3.395-411.1992 ↗
30. Nanotechnology in medicine and antibacterial effect of silver nanoparticles
31. The molecular mechanism of action of bactericidal gold NPs on Escherichia coli10.1016/j.biomaterials.2011.11.057 ↗
32. Proteomic analysis of the mode of antibacterial action of silver NPs10.1021/pr0504079 ↗
33. Characterization of enhanced antibacterial effects of novel silver nanoparticles10.1088/0957-4484/18/22/225103 ↗
34. Antimicrobial effects of silver NPs10.1016/j.nano.2006.12.001 ↗
35. Preparation and antibacterial activity of Fe3O4@Ag NPs10.1088/0957-4484/18/28/285604 ↗
36. Biogenic synthesis of silver NPs and their synergistic effect with antibiotics: A study against gram-positive and gram-negative bacteria10.1016/j.nano.2009.04.006 ↗
37. In vitro antimicrobial studies of silver carbene complexes: Activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria10.1093/jac/dkr408 ↗
38. Toxicity and antimicrobial activity of a hydrocolloid dressing containing silver particles in an ex vivo model of cutaneous infection10.1159/000074060 ↗
39. Acticoat versus silverlon: The truth10.1097/00004630-200203002-00146 ↗
40. Antimicrobial activities of silver dressings: An in vitro comparison10.1099/jmm.0.46124-0 ↗
41. Preparation and characterization of antibacterial silver-containing nanofifibers for wound dressing applications
42. Antibacterial activity and cytocompatibility of titanium oxide coating modified by iron ion implantation10.1016/j.actbio.2014.06.002 ↗
43. Antimicrobial activity of tantalum oxide coatings decorated with Ag nanoparticles10.1116/1.4947077 ↗
44. Exposure-related health effects of silver and silver compounds: A review
45. Silver NPs: Synthesis, properties, and therapeutic applications10.1016/j.drudis.2014.11.014 ↗
46. Antibacterial activity of glutathione-coated silver nanoparticles against gram positive and gram negative bacteria10.1021/la3003838 ↗
47. Effect of plasma coating on antibacterial activity of silver nanoparticles10.1016/j.tsf.2018.12.049 ↗
48. Metal-based NPs and their toxicity assessment10.1002/wnan.103 ↗
49. Nanomedicine(s) under the microscope10.1021/mp200394t ↗
50. Nanotechnology applied to the treatment of malaria10.1016/j.addr.2009.11.024 ↗
51. Nanomedicine in pulmonary delivery10.2147/IJN.S4937 ↗
52. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery10.1016/j.addr.2009.11.023 ↗
53. Development of NPs for antimicrobial drug delivery10.2174/092986710790416290 ↗
54. Drug delivery approaches to overcome bacterial resistance to β-lactam antibiotics10.1517/17425247.5.9.931 ↗
55. Stealth liposomes
56. Novel applications of liposomes10.1016/S0167-7799(98)01220-7 ↗
57. Liposome-encapsulted ampicillin: Physicochemical and antibacterial properties10.1021/js9503690 ↗
58. Liposome-incorporated ciproflfloxacin in treatment of murine salmonellosis10.1128/AAC.37.11.2293 ↗
59. Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin10.1007/BF01715542 ↗
60. Chemotherapentic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice10.1093/jac/28.3.425 ↗
61. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection10.1016/S0006-2952(02)01346-1 ↗
62. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies10.1093/jac/48.3.333 ↗
63. The delivery of benzyl penicillin to Staphylococcus aureus10.1081/LPR-200029887 ↗
64. Cosmetic applications for solid lipid NPs (SLN)10.1016/S0378-5173(02)00684-1 ↗
65. Solid lipid NPs (SLN) for controlled drug delivery—A review of the state of the art10.1016/S0939-6411(00)00087-4 ↗
66. Solid lipid particle-based inhalable sustained drug delivery system against experimenta tuberculosis10.1016/j.tube.2004.11.003 ↗
67. Solid lipid NPs (SLN) as ocular delivery system for tobramycin10.1016/S0378-5173(02)00080-7 ↗
68. Solid lipid NPs (SLN) as carriers for the topical delivery of econazole nitrate: In-vitro characterization, ex-vivo and in-vivo studies10.1211/jpp.59.8.0002 ↗
69. Comparison of ciproflfloxacin hydrochloride-loaded protein, lipid, and chitosan NPs for drug delivery10.1002/jbm.b.30994 ↗
70. Treatment of experimental salmonellosis in mice with ampicillin-bound NPs10.1128/AAC.33.9.1540 ↗
71. Penicillin-bound polyacrylate NPs: Restoring the activity of β- lactam antibiotics against MRSA10.1016/j.bmcl.2007.03.077 ↗
72. Antibiotic-conjugated polyacrylate NPs: New opportunities for development of anti-MRSA agents10.1016/j.bmcl.2006.09.098 ↗
73. In vitro antileishmanial activity of amphotericin B loaded in poly(1-Caprolactone) nanospheres10.1080/1061186021000060738 ↗
74. Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages10.1093/jac/30.2.173 ↗
75. The antimicrobial activity of nanoparticles: Present situation and prospects for the future10.2147/IJN.S121956 ↗
76. Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration10.1016/0378-5173(86)90081-5 ↗
77. Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review10.1016/j.ejpb.2013.07.002 ↗